Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
RESEARCH TOOLSreports
Top Page
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
Rating:55Neutral
Price Target:
$5.00
▲(6.38%Upside)
Positive Factors
Clinical Trial Results
Clinical trial results show promising response rates in patients treated with motixafortide combo for pancreatic cancer.
Financial Performance
The company reported EPS of $1.39, which was significantly higher than the analyst's estimate of ($0.84).
Partnerships and Opportunities
Positive trial results may offer BLRX additional opportunities to partner the asset or fund a pivotal trial.
Negative Factors
Adverse Events
The most common Grade ≥ III adverse events in the trial were anemia and rash, which could impact patient outcomes.
Revenue Projections
Risk-adjusted revenue from motixafortide in metastatic pancreatic cancer has been removed, reducing the probability of success from 2.5% to 0%.
Bioline RX Ltd Sponsored ADR (BLRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.28M
Dividend YieldN/A
Average Volume (3M)1.40M
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue Growth91.68%
EPS Growth90.86%
CountryUS
Employees28
SectorHealthcare
Sector Strength39
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,262,685
10 Day Avg. Volume38,192
30 Day Avg. Volume1,396,909
Financial Highlights & Ratios
PEG Ratio-66.23
Price to Book (P/B)394.75
Price to Sales (P/S)0.00
P/FCF Ratio-579.47
Enterprise Value/Market Cap683.85
Enterprise Value/Revenue165.53
Enterprise Value/Gross Profit669.91
Enterprise Value/Ebitda-166.21
Forecast
1Y Price Target
$14.17Price Target Upside201.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company DescriptionBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
How the Company Makes MoneyBioline RX Ltd generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales generated from any successfully commercialized products. The company may also receive funding from grants or government support for its research endeavors. Bioline RX's financial performance is significantly influenced by the progress of its clinical trials, regulatory approvals, and the successful commercialization of its therapeutic candidates.
Bioline RX Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date:May 27, 2025
(Q1-2025)
| % Change Since: 28.42%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive outlook with significant achievements in licensing agreements, financial efficiency, and promising clinical trial results in pancreatic cancer. However, there were challenges in revenue generation due to the transition of APHEXDA sales and ongoing efforts to acquire new assets without a definitive outcome yet.Q1-2025 Updates
Positive Updates
Transformational Licensing Agreement with Ayrmid Pharma
Exclusive out-licensing agreement for APHEXDA with Ayrmid Pharma Limited, including upfront payment, significant commercial milestones, and royalties.
Significant Reduction in Operating Cash Burn
Reduced ongoing operating cash burn by over 70% from $40 million to less than $12 million annually.
Positive Financial Position
Net income of $5.1 million for Q1 2025, compared to a net loss of $0.7 million in Q1 2024, primarily due to non-operating income from the revaluation of warrants.
Strong Performance in Pancreatic Cancer Studies
Promising results from CheMo4METPANC trial, including a partial response rate of 64% and a disease control rate of 91%, with some patients showing significant long-term progression-free survival.
Encouraging APHEXDA Sales Under Ayrmid
APHEXDA sales generated $1.4 million in Q1 2025, resulting in $0.3 million of royalty revenues to BioLineRx.
Robust Cash Position
Ended Q1 2025 with $26.4 million in cash, cash equivalents, and short-term bank deposits, with a cash runway projected through the second half of 2026.
Negative Updates
Decrease in Total Revenues
Total revenues for Q1 2025 were $0.3 million, compared to $6.9 million in Q1 2024, primarily due to the transition of APHEXDA sales to Ayrmid.
Challenges in Sickle Cell Disease Treatment
Stem cell mobilization remains a challenge for sickle cell disease patients, with ongoing trials still in early phases.
Uncertainty in New Asset Acquisition
Ongoing search and evaluation of new assets in oncology and rare diseases, but no definitive announcements yet.
Company Guidance
During BioLineRx's Q1 2025 financial results call, the company highlighted several key metrics and strategic moves. The partnership with Ayrmid Pharma Limited, which started in 2024, resulted in $1.4 million in APHEXDA sales for Q1 2025, generating $0.3 million in royalty revenue for BioLineRx. The company's financials showed a significant reduction in operating expenses, with operating cash burn reduced by over 70% from $40 million to under $12 million annually, following a restructuring that included a headcount reduction and the shutdown of U.S. operations. BioLineRx ended the quarter with $26.4 million in cash, with a runway expected to last through the second half of 2026. The call detailed ongoing clinical developments, including a Phase 2b study of motixafortide in pancreatic cancer, with a planned interim analysis in 2026. The company continues to evaluate potential in-licensing opportunities to expand its pipeline, leveraging expertise in oncology and rare diseases.Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
BioLine RX Ltd shows significant revenue growth, suggesting potential future profitability. However, challenges persist with negative net income, high leverage, and weak cash generation from operations. While the ability to raise funds is positive, overall financial health remains challenged by profitability and cash flow issues.Income Statement
The company has shown significant revenue growth from 2023 to 2024, with a surge from $4.8 million to $28.94 million. However, the net profit margin remains negative, indicating ongoing profitability challenges. The negative EBIT margin highlights persistent operating losses, though the transition from a negative to a positive EBITDA margin suggests some improvement in operational efficiency.25
Negative
Balance Sheet
The debt-to-equity ratio is relatively high at 1.12, indicating a heavy reliance on debt financing which could pose risks in terms of financial stability. The equity ratio has decreased, reflecting a reduced capacity to cover assets with equity. Despite these challenges, the company maintains a positive stockholders’ equity, indicating some level of financial health.40
Negative
Cash Flow
The free cash flow remains negative, although there is a notable increase in financing inflows, reflecting the company's ability to raise funds. However, the operating cash flow to net income ratio is negative, suggesting that cash generation from operations is weak, which could impact long-term sustainability.30
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.94M | 4.80M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 19.68M | 1.11M | 0.00 | 0.00 | 0.00 |
| EBITDA | 3.92M | -57.09M | -28.50M | -24.07M | -22.34M |
| Net Income | -9.22M | -60.61M | -20.75M | -28.14M | -30.93M |
Balance Sheet | |||||
| Total Assets | 38.91M | 63.92M | 76.38M | 81.39M | 47.29M |
| Cash, Cash Equivalents and Short-Term Investments | 19.56M | 42.99M | 51.08M | 57.13M | 22.59M |
| Total Debt | 15.04M | 11.59M | 12.32M | 4.65M | 7.68M |
| Total Liabilities | 25.45M | 50.70M | 25.54M | 13.30M | 25.26M |
| Stockholders Equity | 13.46M | 13.22M | 50.84M | 68.09M | 22.03M |
Cash Flow | |||||
| Free Cash Flow | -43.93M | -22.91M | -26.56M | -23.67M | -23.21M |
| Operating Cash Flow | -43.87M | -22.61M | -26.24M | -23.57M | -23.21M |
| Investing Cash Flow | 29.37M | 1.44M | 4.01M | -38.22M | 16.67M |
| Financing Cash Flow | 20.66M | 15.06M | 20.44M | 57.75M | 17.87M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Positive
4.70
Price Trends
4.15
Positive
3.65
Positive
8.11
Negative
Market Momentum
0.10
Positive
57.59
Neutral
75.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Positive. The current price of 4.7 is above the 20-day moving average (MA) of 4.59, above the 50-day MA of 4.15, and below the 200-day MA of 8.11, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 57.59 is Neutral, neither overbought nor oversold. The STOCH value of 75.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline RX Ltd Sponsored ADR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $14.28M | 0.77 | -162.42% | ― | -82.24% | ― | |
55 Neutral | $19.28M | ― | -20.03% | ― | 91.68% | 90.86% | |
52 Neutral | $7.59B | 0.30 | -61.86% | 2.27% | 16.72% | 1.10% | |
47 Neutral | $13.89M | ― | -7.72% | ― | 35.25% | 81.05% | |
43 Neutral | $79.47M | ― | -27.00% | ― | 1904.43% | 93.72% | |
40 Underperform | $9.79M | ― | -59.80% | ― | 157.63% | 40.52% | |
27 Underperform | $7.50M | ― | -342.99% | ― | ― | 99.64% |
* Healthcare Sector Average
Performance Comparison
BLRX
Bioline RX Ltd Sponsored ADR
4.70
-23.85
-83.54%
TXMD
TherapeuticsMD
1.18
-0.67
-36.22%
ABVC
ABVC BioPharma
3.97
3.18
402.53%
APRE
Aprea Therapeutics
1.73
-2.38
-57.91%
ADXN
Addex Therapeutics
8.83
0.53
6.39%
RNAZ
TransCode Therapeutics
8.68
-783.19
-98.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.